Sign in to view content

Treatment Response to Antioxidant Supplementation Based on CFH and ARMS2Â Genetic Risk Allele Number in AREDS Patients With No AMD at Baseline

Carl C. Awh, MD, FASRS

Video
Published 2016

Related

Interim Results and Key Learnings from an Ongoing Phase 2 Study of Encapsulated Cell Therapy Compared to Aflibercept in Patients With Wet AMD
Szilárd Kiss, MD
Annual Meeting Talks
2016
Visual Loss After Cosmetic Facial Filler Injection
Min Kim, MD, PhD, MBA, FASRS
Annual Meeting Talks
2016
The OASIS Trial: Efficacy and Safety Outcomes in Subjects With Full-Thickness Macular Hole
Michael Tolentino, MD
Annual Meeting Talks
2016

Category: AMD-Non-Neovascular

See more